Emerging drugs for treatment of anemia of chronic kidney disease

被引:4
|
作者
Magwood, Jametta S. [1 ,2 ]
Lebby, Akida [1 ,2 ]
Chen, Brian [1 ,2 ,4 ]
Kessler, Sam [1 ,2 ]
Norris, LeAnn [1 ,2 ,3 ]
Bennett, Charles L. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA
[2] Southern Network Adverse React SONAR, Columbia, SC USA
[3] WJB Dorn VA Med Ctr, Columbia, SC USA
[4] Arnold Sch Publ Hlth, Columbia, SC USA
[5] Hollings Canc Ctr, Charleston, SC USA
关键词
anemia; chronic kidney disease; erythropoietin; peginesatide; ERYTHROPOIESIS-STIMULATING AGENTS; RED-CELL APLASIA; EPOETIN-ALPHA; DARBEPOETIN ALPHA; CANCER; PEGINESATIDE; METAANALYSIS; MORTALITY; STABILIZATION; HEMODIALYSIS;
D O I
10.1517/14728214.2013.836490
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Erythropoiesis-stimulating agents (ESAs) prevent transfusions among anemic patients with chronic kidney disease (CKD). Clinical trials, meta-analyses, and guidelines identify arterial and venous thromboembolism as well as myocardial event risks with the traditional ESAs, erythropoietin (EPO), and darbepoietin. Side effects of anemia treatment, considering frequency and dosage of treatment as well as targeted hemoglobin levels when utilizing ESAs, greatly impact overall well-being and the quality of life. There is a need for less frequent but equally effective ESAs in this setting. Areas covered: The three generations of ESAs used in CKD-associated anemia are described. Cost effectiveness of the utilization of these therapies, in addition to emerging therapies, is also presented. The few clinical and controlled trials only highlight the need for clarity in molecular biology surrounding the components that control EPO levels and utilization. Expert opinion: Anemia associated with CKD is an important area for development of newer therapies which are potentially safer and more convenient to administer.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [41] Anemia in children with chronic kidney disease
    Koshy, Susan M.
    Geary, Denis F.
    PEDIATRIC NEPHROLOGY, 2008, 23 (02) : 209 - 219
  • [42] Anemia in children with chronic kidney disease
    Atkinson, Meredith A.
    Furth, Susan L.
    NATURE REVIEWS NEPHROLOGY, 2011, 7 (11) : 635 - 641
  • [43] Anemia and the heart in chronic kidney disease
    Zalunardo, Nadia
    Levin, Adeera
    SEMINARS IN NEPHROLOGY, 2006, 26 (04) : 290 - 295
  • [44] Diabetes treatment with oral antidiabetic drugs in chronic kidney disease
    Merker, L.
    Kleophas, W.
    NEPHROLOGE, 2018, 13 (06): : 425 - 434
  • [45] Novel drugs and intervention strategies for the treatment of chronic kidney disease
    Heerspink, Hiddo Jan Lambers
    de Zeeuw, Dick
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (04) : 536 - 550
  • [46] Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
    Bradley A. Warady
    Mazen Y. Arar
    Gary Lerner
    Arline M. Nakanishi
    Catherine Stehman-Breen
    Pediatric Nephrology, 2006, 21 : 1144 - 1152
  • [47] Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease
    Coyne, Daniel W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (15) : 2563 - 2568
  • [48] Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
    Warady, Bradley A.
    Arar, Mazen Y.
    Lerner, Gary
    Nakanishi, Arline M.
    Stehman-Breen, Catherine
    PEDIATRIC NEPHROLOGY, 2006, 21 (08) : 1144 - 1152
  • [49] Treatment of anemia in difficult-to-manage patients with chronic kidney disease
    Raichoudhury, Ritesh
    Spinowitz, Bruce S.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 26 - 34
  • [50] The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease
    Yarnoff, Benjamin O.
    Hoerger, Thomas J.
    Simpson, Siobhan A.
    Pavkov, Meda E.
    Burrows, Nilka R.
    Shrestha, Sundar S.
    Williams, Desmond E.
    Zhuo, Xiaohui
    PLOS ONE, 2016, 11 (07):